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BACKGROUND: Considerable variation in intravenous 5-fluorouracil (5-FU)
metabolism can occur due to the wide range of dihydropyrimidine dehydrogenase
(DPD) enzyme activity, which can affect both tolerability and efficacy. The oral
fluoropyrimidine tegafur-uracil (UFT) is an effective, well-tolerated and convenient
alternative to intravenous 5-FU. We undertook this study in patients with locally
advanced rectal cancer to evaluate the efficacy and tolerability of UFT with
leucovorin (LV) and preoperative radiotherapy and to evaluate the utility and
limitations of multicenter staging using pre- and post-chemoradiotherapy ultrasound.
We also performed a validated pretherapy assessment of DPD activity and assessed
its potential influence on the tolerability of UFT treatment. METHODS: This phase II
study assessed preoperative UFT with LV and radiotherapy in 85 patients with locally
advanced T3 rectal cancer. Patients with potentially resectable tumors received UFT
(300 mg/m/2/day), LV (75 mg/day), and pelvic radiotherapy (1.8 Gy/day, 45 Gy total) 5
days/week for 5 weeks then surgery 4-6 weeks later. The primary endpoints included
tumor downstaging and the pathologic complete response (pCR) rate. RESULTS:
Most adverse events were mild to moderate in nature. Preoperative grade 3/4 adverse
events included diarrhea (n = 18, 21%) and nausea/vomiting (n = 5, 6%). Two
patients heterozygous for dihydropyrimidine dehydrogenase gene (DPYD)
experienced early grade 4 neutropenia (variant IVS14+1G > A) and diarrhea (variant
2846A > T). Pretreatment ultrasound TNM staging was compared with
postchemoradiotherapy pathology TN staging and a significant shift towards earlier
TNM stages was observed (p < 0.001). The overall downstaging rate was 42% for
primary tumors and 44% for lymph nodes. The pCR rate was 8%. The sensitivity and
specificity of ultrasound for staging was poor. Anal sphincter function was preserved
in 55 patients (65%). Overall and recurrence-free survival at 3 years was 86.1% and
66.7%, respectively. Adjuvant chemotherapy was administered to 36 node-positive
patients (mean duration 118 days). CONCLUSION: Preoperative chemoradiotherapy
using UFT with LV plus radiotherapy was well tolerated and effective and represents
a convenient alternative to 5-FU-based chemoradiotherapy for the treatment of
resectable rectal cancer. Pretreatment detection of DPD deficiency should be
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